Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HanAll BioPharma Co. Ltd.

Division of Daewoong Pharmaceutical Co. Ltd.
www.hanall.co.kr

Latest From HanAll BioPharma Co. Ltd.

KDDF’s Support Reflected In Robust R&D, Licensing By Korean Firms

Various government support schemes seem to have led to recent successful new drug development activities and licensing deals by South Korean pharma and biotech firms. The state-run Korea Drug Development Fund is seen as having played a key role in this effort, providing assistance to 153 R&D programs in the country so far to speed up development of novel and innovative global medicines.
Research & Development South Korea

Korean Pharma Finds Own Way To Collaborative And Open Innovation

Taking into consideration global and domestic trends, South Korean pharmas are increasingly finding their own strategies to seek open innovation and collaborations to develop novel new drugs. Two leading firms from the country shared their know-how and showcased successful open innovation cases during a recent gathering organized by a national industry association.

South Korea Innovation

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Business Strategies Companies

China's Harbour BioMed Mulls Global Licensing

The Shanghai-based biotech startup Harbour Biomed hopes overseas licensing will propel it towards an initial offering in the US, following in the footsteps of a successful approach pioneered by BeiGene.

China Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • HanAll Pharmaceutical Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Daewoong Pharmaceutical Co. Ltd.
  • Senior Management
  • Seungkook Park, PhD, CEO
    Hansoo Lee, Exec. Dir., Fin.
  • Contact Info
  • HanAll BioPharma Co. Ltd.
    Phone: (82) 02-550-8800
    Daewoong Bldg. Fl9, 12 Bongeunsaro 114
    Seoul, 138-922
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register